03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: BCL6 corepressor (BCOR) gene aberrations as a diagnostic marker for clear cell sarcoma of the kidney

Biomarkers TECHNOLOGY: Gene profiling BCL6 corepressor (BCOR) National Research Institute for Child Health and Development...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Subtype-specific somatic mutations in medulloblastoma Identification of new subtype-specific somatic mutations in medulloblastoma could aid the development of new treatments for the disease. Whole-exome hybrid capture...
01:22 , Dec 2, 2006 |  BC Extra  |  Company News

Ullman leaving Biovitrum as head of R&D

Metabolic company Biovitrum (SSE:BVT) said head of R&D Anders Ullman will depart, effective Dec. 31, to become head of R&D at Nycomed (Roskilde, Denmark). BVT's R&D group will now report to CEO Mats Pettersson. BVT...
07:00 , Jun 26, 2006 |  BC Week In Review  |  Company News

Biacore, General Electric deal

GE’s GE Healthcare unit offered to acquire BCOR for SEK330 per share, or SEK3.2 billion ($438.6 million) in cash. The price is a 17% premium to BCOR’s close of SEK282 on June 19, the day...
07:00 , Jun 26, 2006 |  BioCentury  |  Finance

Ebb & Flow

Speculators start your engines. Last week saw developments in the insomnia space that have analysts and investors pondering the futures of Sepracor (SEPR) and Neurocrine (NBIX). SEPR started the week with a 9% pop on...
01:18 , Jun 21, 2006 |  BC Extra  |  Company News

GE Healthcare to acquire Biacore

GE Healthcare, a unit of General Electric (GE), offered to acquire Biacore (SSE:BCOR) for SEK330 per share, or SEK3.2 billion ($438.6 million) in cash. The price is a 17% premium to BCOR's close of SEK282...
07:00 , Apr 17, 2006 |  BioCentury  |  Finance

Ebb & Flow

For most of the first quarter, the BioCentury 100 Index moved in concert with the broader markets. But in the past four weeks, the BioCentury 100 has diverged to the downside. The benchmark is down...
08:00 , Jan 2, 2006 |  BioCentury  |  Finance

Tier jumpers

Tier jumpers Tier jumpers No fewer than 56 biotech companies will start 2006 in a higher market cap band than they started in in 2005. Many of the companies graduated because of fundamental progress in...